XLIMus Drug Eluting Stent: a randomIzed Controlled Trial to Assess Endothelization

Inclusion Criteria: 1. Age≥18 2. Documented coronary artery disease (CAD): stable or unstable angina, Non-ST segment MI. 3. PCI considered appropriate and feasible 4. Culprit de novo lesion in a native coronary artery with significant stenosis (\>50% by visual estimate) eligible for implantation with either study stent (no limitation on the number of treated lesions, vessel and lesion length); 5. Patient provides written informed consent 6. Patient agrees to all required follow-up procedures and visits. 7. Target lesion suitable for PCI with DES diameter between 2.5 and 4.0 mm Exclusion Criteria: 1. The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, ticlopidine, sirolimus or its derivatives, everolimus or structurally-related compounds, and/or contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled); 2. Known hypersensitivity to L605 cobalt chromium, 316L stainless steel, platinum, chromium, iron, nickel or molybdenum; 3. Known sensitivity to poly-lactic acid or poly(lactic-co-glycolic acid) polymer; 4. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrolment into this study and not using adequate contraceptive methods; 5. History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions; 6. Previous coronary intervention on target vessel in the 3-months prior to enrollment; 7. Non-cardiac co-morbid conditions with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment); 8. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period; 9. Previously documented left ventricular ejection fraction (LVEF) \<30%; 10. Evident cardiogenic shock before randomization; 11. Patients with left main stem stenosis (\>50% by visual estimate); 12. In-stent restenosis; 13. ST-segment elevation MI; 14. Chronic total occlusion/ heavily calcified lesions 15. Culprit lesion to a Saphenous Vein graft